Anika Therapeutics, Inc. (ANIK) is a Medical - Devices company in the Healthcare sector, currently trading at $15.28. It has a SharesGrow Score of 29/100, indicating a weak investment profile with 0 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ANIK = $1,004.67 (+6475.1% from the current price, the stock appears undervalued).
Valuation: ANIK trades at a trailing Price-to-Earnings (P/E) of -19.9 (S&P 500 average ~25).
Financials: revenue is $113M, -9.1%/yr average growth. Net income is $11M (loss), growing at -114.6%/yr. Net profit margin is -9.6% (negative). Gross margin is 56.6% (-3.3 pp trend).
Balance sheet: total debt is $24M against $143M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 4.72 (strong liquidity). Debt-to-assets is 12.7%. Total assets: $190M.
Analyst outlook: 3 / 6 analysts rate ANIK as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 49/100 (Partial), Future 40/100 (Partial), Income 10/100 (Fail).
